Chenxi Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenxi Yu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Susan Halabi
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA
20 shared publications - Andrew J. Armstrong
Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, USA
18 shared publications - Anna Kobilka
University of Minnesota 3 Masonic Cancer Center Minneapolis, Minnesota
17 shared publications - Bin Luo
Computer Science, Kennesaw State University, Marietta, GA, USA
17 shared publications - Charles J. Ryan
Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, Minnesota
17 shared publications - Emmanuel S. Antonarakis
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
17 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (23-24)
Group Sequential Sample Size for Comparing Two Survival Probabilities at a Specific Time Point
We propose a novel method that simultaneously determines the sample size for testing two survival probabilities at a pre‐specified time while guaranteeing Type I error control in both fixed and group‐sequential trial designs. Simulations across varying hypothesized differences, failure distributions, censoring proportions, and nominal powers demonstrate consistent performance, while interim analyses highlight maintained nominal Type I error control and increased power at each look relative to the standard binomial approach, regardless of the underlying failure time distribution or spending function. Importantly, our method is especially useful for evaluating survival outcomes at a fixed time in randomized trials where one treatment arm includes neoadjuvant therapy prior to surgery while the other involves surgery alone. Furthermore, it is advantageous when the proportional hazards assumption is not satisfied, as often occurs in immunotherapy trials with delayed or time‐varying treatment effects or crossing survival curves. The method is also applicable to randomized Phase II trials, where smaller sample sizes and the use of intermediate or surrogate time‐to‐event endpoints demand efficient data use and robust error control. We illustrate the approach with motivating examples in renal and prostate cancer. An accompanying R Shiny application enables investigators to compute sample sizes interactively, facilitating practical trial planning in diverse settings.
- 9 October 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (23-24)
Group Sequential Sample Size for Comparing Two Survival Probabilities at a Specific Time Point
We propose a novel method that simultaneously determines the sample size for testing two survival probabilities at a pre‐specified time while guaranteeing Type I error control in both fixed and group‐sequential trial designs. Simulations across varying hypothesized differences, failure distributions, censoring proportions, and nominal powers demonstrate consistent performance, while interim analyses highlight maintained nominal Type I error control and increased power at each look relative to the standard binomial approach, regardless of the underlying failure time distribution or spending function. Importantly, our method is especially useful for evaluating survival outcomes at a fixed time in randomized trials where one treatment arm includes neoadjuvant therapy prior to surgery while the other involves surgery alone. Furthermore, it is advantageous when the proportional hazards assumption is not satisfied, as often occurs in immunotherapy trials with delayed or time‐varying treatment effects or crossing survival curves. The method is also applicable to randomized Phase II trials, where smaller sample sizes and the use of intermediate or surrogate time‐to‐event endpoints demand efficient data use and robust error control. We illustrate the approach with motivating examples in renal and prostate cancer. An accompanying R Shiny application enables investigators to compute sample sizes interactively, facilitating practical trial planning in diverse settings.
- Open Access
Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Purpose:Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis.Experimental Design:We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points.Results:Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extre mes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression.Conclusions:AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.See related commentary by Chauhan et al., p. 2323
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Purpose:Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis.Experimental Design:We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points.Results:Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extre mes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression.Conclusions:AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.See related commentary by Chauhan et al., p. 2323
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 2. cfDNA yield, tumor aneuploidy fraction, group, and ctDNA detection in A031201 cfDNA
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 2. cfDNA yield, tumor aneuploidy fraction, group, and ctDNA detection in A031201 cfDNA
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Figure 3. Alterations in ctDNA-positive samples containing potential clonal hematopoiesis mutations.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Figure 3. Alterations in ctDNA-positive samples containing potential clonal hematopoiesis mutations.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Table 1: Representativeness of Study Participants
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Table 1: Representativeness of Study Participants
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S4 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 4. Counts of AR-GSRs detected in A031201 cfDNA
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S4 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 4. Counts of AR-GSRs detected in A031201 cfDNA
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Figure 5. Longitudinal analysis of pathogenic AR SNVs in matched baseline and progression ctDNA
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Figure 5. Longitudinal analysis of pathogenic AR SNVs in matched baseline and progression ctDNA
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Table 2. Genes analyzed in the AR-ctDETECT pipeline
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Table 2. Genes analyzed in the AR-ctDETECT pipeline
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S5 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 5. DNA-seq coverage and log2 copy number ratios of targeted genes relative to control regions
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S5 from Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Supplementary Data 5. DNA-seq coverage and log2 copy number ratios of targeted genes relative to control regions